Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,221 to 3,240 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Foley Bulb Plus Oral Misoprostol vs Oral Misoprostol: Number of Participants With Blood Transfusion | 37 of 1,117 33 of 1,110 | 0.3 points -1.1 to 1.8 | 2,227 | NCT03407625 Foley Bulb With Oral Misoprostol for Induction of Labor |
| Foley Bulb Plus Oral Misoprostol vs Oral Misoprostol: Number of Participants That Needed Mechanical Ventilation in Delivery Room (Yes/No) | 2 of 1,117 4 of 1,110 | -0.2 points -0.8 to 0.3 | 2,227 | NCT03407625 Foley Bulb With Oral Misoprostol for Induction of Labor |
| Foley Bulb Plus Oral Misoprostol vs Oral Misoprostol: Number of Participants With Excess Blood Loss | 215 of 1,117 223 of 1,110 | -0.8 points -4.1 to 2.5 | 2,227 | NCT03407625 Foley Bulb With Oral Misoprostol for Induction of Labor |
| Foley Bulb Plus Oral Misoprostol vs Oral Misoprostol: Number of Participants Used General Anesthesia for Delivery | 29 of 1,117 24 of 1,110 | 0.4 points -0.9 to 1.7 | 2,227 | NCT03407625 Foley Bulb With Oral Misoprostol for Induction of Labor |
| Whole Breast Irradiation + Sequential Boost vs Hypofractionated Whole Breast Irradiation + Concurrent Boost: serious adverse events | 18 of 1,100 20 of 1,123 | -0.1 points -1.3 to 1.0 | 2,223 | NCT01349322 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery |
| CDB-2914 vs Levonorgestrel: Number of Participants With Pregnancy | 20 of 1,104 30 of 1,117 | -0.9 points -2.2 to 0.4 | 2,221 | NCT00551616 Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception |
| CDB-2914 vs Levonorgestrel: serious adverse events | 3 of 1,104 4 of 1,117 | -0.1 points -0.7 to 0.5 | 2,221 | NCT00551616 Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception |
| Intervention Group vs Control Group: Number of Participants Reporting Alcohol/Marijuana Use | 122 of 988 204 of 1,233 | -4.2 points -7.1 to -1.2 | 2,221 | NCT02909673 School Based Program to Prevent Teen Dating Violence |
| NOMAC-E2 vs DRSP-EE: serious adverse events | 32 of 1,666 6 of 554 | 0.8 points -0.5 to 1.8 | 2,220 | NCT00413062 Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722) |
| Sulopenem Etzadroxil/Probenecid vs Amoxicillin/Clavulanate: Clinical Success Modified Intent-to-treat Population | 851 of 1,107 849 of 1,107 | 0.2 points -3.3 to 3.7 | 2,214 | NCT05584657 Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women |
| Sulopenem Etzadroxil/Probenecid vs Amoxicillin/Clavulanate: serious adverse events | 0 of 1,107 5 of 1,107 | -0.5 points -1.1 to -0.0 | 2,214 | NCT05584657 Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women |
| PG Dosing Patients vs Historical Controls: serious adverse events | 22 of 487 162 of 1,726 | -4.9 points -7.0 to -2.3 | 2,213 | NCT00927862 Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin |
| TDF/FTC vs Placebo: Condomless Receptive Anal Intercourse in the Previous 12 Weeks With Any Partners Regardless of Status. | 332 of 1,091 348 of 1,114 | -0.8 points -4.7 to 3.0 | 2,205 | NCT00458393 Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men |
| Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With Heart Failure Death | 8 of 1,108 7 of 1,096 | 0.1 points -0.7 to 0.9 | 2,204 | NCT00911508 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial |
| Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With Mortality, Disabling Stroke, or CV Hospitalization (for Heart Failure or Acute Ischemic Events) | 170 of 1,108 189 of 1,096 | -1.9 points -5.0 to 1.2 | 2,204 | NCT00911508 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial |
| Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With Mortality or Cardiovascular (CV) Hospitalization | 573 of 1,108 637 of 1,096 | -6.4 points -10.5 to -2.3 | 2,204 | NCT00911508 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial |
| Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With an Arrhythmic Death or Cardiac Arrest | 10 of 1,108 13 of 1,096 | -0.3 points -1.2 to 0.6 | 2,204 | NCT00911508 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial |
| Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With All-cause Mortality | 58 of 1,108 67 of 1,096 | -0.9 points -2.8 to 1.1 | 2,204 | NCT00911508 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial |
| Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With Composite of Total Mortality, Disabling Stroke, Serious Bleeding, or Cardiac Arrest in Patients Warranting Therapy for AF. | 89 of 1,108 101 of 1,096 | -1.2 points -3.5 to 1.2 | 2,204 | NCT00911508 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial |
| Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With Cardiovascular Death | 22 of 1,108 23 of 1,096 | -0.1 points -1.3 to 1.1 | 2,204 | NCT00911508 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial |
Code
curl "https://conductscience.org/api/comparisons/v1?page=162"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=162
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03407625-bca4a802",
"title": "Foley Bulb Plus Oral Misoprostol vs Oral Misoprostol: Number of Participants With Blood Transfusion",
"summary": "37 of 1117 against 33 of 1110; risk difference 0.3 points, 95% interval -1.1 to 1.8; NCT03407625, Foley Bulb With Oral Misoprostol for Induction of Labor",
"record": "/library/comparisons/NCT03407625-bca4a802",
"nct_id": "NCT03407625",
"kind": "outcome",
"participants": 2227,
"risk_difference": {
"value": 0.0033947107358029485,
"lower": -0.011386856870000402,
"upper": 0.018253110099718514
},
"group_1": "37 of 1,117",
"group_2": "33 of 1,110",
"difference": "0.3 points",
"interval": "-1.1 to 1.8",
"trial_title": "Foley Bulb With Oral Misoprostol for Induction of Labor"
},
{
"id": "NCT03407625-ca9503d4",
"title": "Foley Bulb Plus Oral Misoprostol vs Oral Misoprostol: Number of Participants That Needed Mechanical Ventilation in Delivery Room (Yes/No)",
"summary": "2 of 1117 against 4 of 1110; risk difference -0.2 points, 95% interval -0.8 to 0.3; NCT03407625, Foley Bulb With Oral Misoprostol for Induction of Labor",
"record": "/library/comparisons/NCT03407625-ca9503d4",
"nct_id": "NCT03407625",
"kind": "outcome",
"participants": 2227,
"risk_difference": {
"value": -0.001813093308169405,
"lower": -0.007586555095471037,
"upper": 0.0033899212489292944
},
"group_1": "2 of 1,117",
"group_2": "4 of 1,110",
"difference": "-0.2 points",
"interval": "-0.8 to 0.3",
"trial_title": "Foley Bulb With Oral Misoprostol for Induction of Labor"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=163",
"request_id": "og-ZJaAJ4Ep4qX89"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant